Tag Archive for: Novo Holdings

Novo Holdings co-leads $181.4 million Series D financing in Alentis Therapeutics to advance groundbreaking antibody-drug conjugates (ADCs) for solid tumours

/in

Funding to support development of first-in-class CLDN1 targeted medicines Strong syndicate of international life science investors One of the largest ADC-focused private fundraisings globally in 2024 Copenhagen, Denmark, 12 November 2024 – Novo Holdings, a leading global life science investor, today announced that it has co-led a $181.4 million Series D financing in Alentis Therapeutics (“Alentis”). […]

Read more

Novo Holdings to acquire majority stake in Stingray Marine Solutions, a leading provider of aquaculture technology

/in

Novo Holdings today announced that it has agreed to acquire a majority stake in Stingray Marine Solutions, a market-leading aquaculture technology company that provides advanced solutions for a more sustainable fish farming industry. Stingray Marine Solutions (“Stingray”), founded in 2012 and headquartered in Oslo, Norway, specialises in intelligent aquaculture technology aimed at increasing sustainable salmon […]

Read more

Novo Holdings Portfolio Company Invetx to be Acquired by Dechra Pharmaceuticals

/in

Transaction values animal health therapeutics pioneer at up to $520 million Novo Holdings co-led Invetx Series B financing round in 2022 Boston, MA, July 18, 2024 – Novo Holdings A/S, a leading international life sciences investor, today announced that its portfolio company, Invetx, has agreed to be acquired by Dechra Pharmaceuticals Limited (“Dechra”), an international veterinary […]

Read more

Asceneuron Secures $100 Million Series C Financing to Advance Groundbreaking Therapeutics in Neurodegenerative Diseases

/in

Financing led by Novo Holdings, including new investment from EQT Life Sciences – LSP Dementia Fund, OrbiMed and SR One with participation from existing investors M Ventures, Sofinnova Partners, GSK Equities Investments Limited and Johnson & Johnson Innovation – JJDC, Inc. Funds will be used to progress lead asset ASN51, an oral small molecule OGA […]

Read more

Novo Holdings co-leads £90 million ($114 million) Series A financing for Myricx Bio to advance a novel payload class for antibody-drug conjugates

/in

Funds will be used to build out Myricx Bio’s proprietary payload platform and advance its pipeline through clinical proof of concept Novo Holdings Venture Investments Partner Michael Bauer will join Myricx Board of Directors and Principal Max Klement will join Myricx Board as an Observer This is the largest European biotech Series A financing this […]

Read more